Pancreatic Cancer News and Research RSS Feed - Pancreatic Cancer News and Research

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.
Implantable device could help deliver toxic cocktail of drugs directly to pancreatic tumors

Implantable device could help deliver toxic cocktail of drugs directly to pancreatic tumors

A highly lethal cancer sometimes requires large doses of highly toxic drugs. However, a blitzkrieg approach can be unfeasible for some patients due to severe side effects. Now a powerhouse team of researchers at the University of North Carolina at Chapel Hill has revealed that an implantable device can deliver a particularly toxic cocktail of drugs directly to pancreatic tumors to stunt their growth or in some cases, shrink them - all while showing signs that the rest of the body would be spared toxic side effects. [More]
VolitionRx initiates study to assess NuQ blood tests for detection of prostate cancer

VolitionRx initiates study to assess NuQ blood tests for detection of prostate cancer

VolitionRx Limited today announced that it has initiated a study to assess the feasibility of using the Company’s NuQ blood tests to detect prostate cancer. The study is in collaboration with the Surrey Cancer Research Institute of the University of Surrey in the UK. [More]
NJHF awards 30 grants for NJ researchers working on health-related research

NJHF awards 30 grants for NJ researchers working on health-related research

New Jersey Health Foundation has awarded 30 grants totaling more than $1 million for researchers in New Jersey who are working on health-related research that demonstrates exciting potential. [More]
Frequent consumption of nuts may reduce risk of breast, colon, pancreatic and lung cancer

Frequent consumption of nuts may reduce risk of breast, colon, pancreatic and lung cancer

Adding nuts to your diet is associated to a reduction in the risk of cancer. This is the main conclusion of multiple studies that have shown that eating 2 or 3 servings per week (57-84 g) of nuts is associated to a reduction in the risk of some types of cancer (breast, colon, pancreatic and lung cancer). [More]
MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug-development company, announces receipt of notice from the U.S. Food and Drug Administration authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer. [More]
Overall EU cancer, leukaemia mortality rates to fall in 2016

Overall EU cancer, leukaemia mortality rates to fall in 2016

Total cancer-related mortality rates for men and women in the European Union will decline in 2016, say researchers who predict falls in death rates from most neoplasms, including leukaemia. [More]
Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Leaders of several cancer centers designated by the National Cancer Institute have united to support human papillomavirus vaccination. Among them is Cheryl Willman, MD, Director and CEO of the University of New Mexico Comprehensive Cancer Center. [More]
Halozyme closes $150 million royalty-backed debt transaction

Halozyme closes $150 million royalty-backed debt transaction

Halozyme Therapeutics, Inc. today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE products, received only from Halozyme's collaborations with Roche and Baxalta. [More]
ROCA Test now available in nine additional U.S. states for early detection of ovarian cancer

ROCA Test now available in nine additional U.S. states for early detection of ovarian cancer

Abcodia, a commercial stage company focused on the development of proprietary tests for the early detection of cancer, today announced expanded U.S. availability of the ROCA Test. [More]
UT Southwestern researchers reveal how CDK4/6-inhibitors alter pancreatic cancer cell metabolism

UT Southwestern researchers reveal how CDK4/6-inhibitors alter pancreatic cancer cell metabolism

UT Southwestern Medical Center researchers have found that cancer drugs known as CDK4/6-inhibitors alter the metabolism of pancreatic cancer cells, revealing a biologic vulnerability that could be exploited for therapeutic gain. [More]
AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology. [More]
Diabetes drug fails to show any benefit against pancreatic cancer

Diabetes drug fails to show any benefit against pancreatic cancer

A diabetes drug that showed promise in previous studies as an anti-cancer treatment failed to show any benefit in a UNC Lineberger Comprehensive Cancer Center-led study that used pancreatic cancer tissue samples to test sensitivity to the drug. [More]
Combining nanomedicine with two anticancer treatments could improve outcomes for pancreatic cancer patients

Combining nanomedicine with two anticancer treatments could improve outcomes for pancreatic cancer patients

A nanoparticle drug-delivery system that combines two complementary types of anticancer treatment could improve outcomes for patients with pancreatic cancer and other highly treatment-resistant tumors while decreasing toxicity. [More]
Only 3% of GPs fully confident and informed about pancreatic cancer symptoms

Only 3% of GPs fully confident and informed about pancreatic cancer symptoms

Just 3% of GPs who responded to a recent survey, commissioned by Pancreatic Cancer Action, said they felt fully confident and informed about the symptoms of pancreatic cancer, and the difficulty in recognising these was deemed to be the main barrier to diagnosing patients early. [More]
WASF3 protein appears to be solid target for reducing cancer metastasis

WASF3 protein appears to be solid target for reducing cancer metastasis

A protein that is constantly expressed by cancer cells and quiescent in healthy ones appears to be a solid target for reducing cancer's ability to spread, scientists report. [More]

First patients treated in Phase 1b trial of pembrolizumab with REOLYSIN in advanced pancreatic adenocarcinoma

Oncolytics Biotech Inc. today announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA) in combination with REOLYSIN (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024). [More]
MGH researchers find how metformin drug prevents progression of pancreatic cancer

MGH researchers find how metformin drug prevents progression of pancreatic cancer

Massachusetts General Hospital investigators may have uncovered a novel mechanism behind the ability of the diabetes drug metformin to inhibit the progression of pancreatic cancer. [More]
LabCorp to offer Interpace's new ThyraMir microRNA classifier test

LabCorp to offer Interpace's new ThyraMir microRNA classifier test

Interpace Diagnostics announced today that Laboratory Corporation of America Holdings, the world's leading health care diagnostics company, will begin offering Interpace's new ThyraMir microRNA classifier test. [More]
New strategy may reduce growth of pancreatic cancers in patients with KRAS gene mutation

New strategy may reduce growth of pancreatic cancers in patients with KRAS gene mutation

University of North Carolina Lineberger Comprehensive Cancer Center researchers have found a promising strategy that may limit the growth of pancreatic cancers in patients with a mutation in a gene called KRAS. [More]
CTCA at Western announces launch of Phase II NivoPlus clinical trial

CTCA at Western announces launch of Phase II NivoPlus clinical trial

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has announced the launch of Phase II of the NivoPlus clinical trial, which combines the immunotherapeutic agent nivolumab with chemotherapy drugs irinotecan and capecitabine. [More]
Advertisement
Advertisement